A Phase 3 Study in Moderate to Severe Psoriasis Patients

Registry ID

EUCTR2011-004350-26

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Eli Lilly and Company

Start date

2012-03-14

Completion date

2019-06-18

Last update

2026-08-16

Conditions

• Moderate to severe plaque psoriasis

Summary

Efficacy of ixekizumab vs. etanercept in subjects with moderate to severe chronic plaque psoriasis based on sPGA and PASI at 12 weeks.

Locations

• , , Netherlands
• , , Spain
• , , Czechia
• , , Austria
• , , Poland
• , , Germany
• , , UK

View on source registry